SRPK1 and prostate carcinoma: As reported, inhibition or knockdown of SRPK1 can remarkably prevent in vitro and in vivo angiogenesis and associated with tumor growth of Wilms’ tumor [34] and prostate cancer [35], highlighting its potential as a novel drug target.